Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

American Journal of Medicine

Volumn 110, Issue 5, 2001, Pages 352-360

  Knapp, Howard H ^a   Schrott, Helmut ^a   Ma, Patrick ^b   Knopp, Robert ^c   Chin, Bruce ^d   Gaziano, J Michael ^e   Donovan, Joanne M ^f   Burke, Steven K ^f   Davidson, Michael H ^g  

^a UNIVERSITY OF IOWA   (United States)

^b Bridgeland Medical Center   (Canada)

^c Northwest Lipid Research Laboratories   (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f GENZYME CORPORATION   (United States)

^g RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; COLESEVELAM; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035313336     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00638-6     Document Type: Article

References (35)

1. The Lipid Research Clinics Coronary Primary Prevention trial results I. Reduction in incidence of coronary heart disease
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
4. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
7. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
8. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial
9. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel II)
10. Cholesterol-lowering diets. A review of the evidence
11. Treating to meet NCEP-recommended LDL-C concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease
12. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia
13. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial
14. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
15. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol
16. Colesevelam hydrochloride (cholestagel): A new potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects
17. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants
18. Colesevelam hydrochloride: Synthesis and testing of a novel polymer gel pharmaceutical
19. Low dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low density lipoprotein cholesterol in patients with primary hypercholesterolemia
20. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements
21. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
22. Range of serum cholesterol values in the population developing coronary artery disease
23. Colesevelam, a novel, highly potent, polymeric bile acid sequestrant significantly lowers LDL-C
24. Colesevelam (Welchol), a new, potent, well-tolerated, non-systemic lipid-lowering agent
25. Drug interactions with colesevelam hydrochloride, a novel potent bile acid binding polymer
26. Drug treatment of lipid disorders
27. Effects of colesevelam HCl (WelChol), a novel, potent bile acid-binding polymer on sterol and bile acid metabolism in type IIa hypercholesterolemic subjects
28. Role of the enterohepatic circulation of bile salts in lipoprotein metabolism
29. Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism
30. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism
31. HMG CoA reductase inhibitors
32. Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment
33. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)